Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals

Journal of Clinical Immunology

Volumn 16, Issue 2, 1996, Pages 115-124

  Nehete, Pramod N ^a   Johnson, Philip C ^b   Schapiro, Steven J ^a   Arlinghaus, Ralph B ^c   Sastry, K Jagannadha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AIDS; Antibody response; Cell mediated immunity; Cross reactivity; HIV 1; Synthetic peptides; T cell proliferation; V3 loop; Vaccine

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SYNTHETIC PEPTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIBODIES; B-LYMPHOCYTES; CELL DIVISION; CROSS REACTIONS; HIV ENVELOPE PROTEIN GP120; HIV SEROPOSITIVITY; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0029930923     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01540958     Document Type: Article

References (40)

1. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF: Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 85: 1932-1936, 1988
2. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 86:6768-6772, 1989
3. Scott Jr CF, Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE: Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIImn strain. Proc Natl Acad Sci USA 87:8597-8601, 1990
4. Baillou A, Brand D, Denis FM, Boup S, Chout R, Goudeau A, Barin F: High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120. AIDS Res Hum Retrovirus 9:1209-1215, 1993
5. Takahashi H, Germain RN, Moss B, Berzofsky JA: An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induced CD4 class II-restricted help for itself. J Exp Med 171:571-576, 1990
6. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette J, De Lisi C, Moss B, Germain RN, Berzofsky JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 85:3105-3109, 1988
7. + cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3 loop of gp120. Virology 188:502-509, 1992
8. Clerici M, Berzofsky JA, Shearer GM, Tacket CO: Exposure to human immunodeficiency virus type 1-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 164:178-182, 1991
9. Berzofsky JA: Development of artificial vaccines against HIV using defined epitopes. FASEB J 5:2412-2418, 1990
10. Larosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dressman GR, Boswell N, Shadduck P. Holley HH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932-935, 1990
11. Myers G, Korber B, Wain-Hobson S, Jeang KT, Henderson LE, Pavlakis GN: Human Reteroviruses and AIDS 1994: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos, NM, Los Alamos National Laboratory, 1994
12. Emini EA, Nara PL, Schleif WA, Lewis JA, Davide JP, Lee RD, Kessler J, Conley S, Matsushita S, Putney SD, Gerety RJ, Eichberg JW: Antibody-mediated in vitro neutralization of human immunodeficiency virus type I abolishes infectivity for chimpanzees. J Virol 64:3674-3678, 1990
13. Neurath AR, Jiang S, Strick N, Kolbe H, Kieny MP, Muchmore E, Girard M: Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loop of HIV-1 envelope glycoproteins. AIDS Res Hum Retrovirus 7:813-823, 1991
14. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730, 1992
15. Nara PL, Smith L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J: Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type I IIIB infection of chimpanzees. J Virol 64:3779-3791, 1990
16. Nehete PN, Murthy KK, Satterfield WC, Arlinghaus RB, Sastry KJ: Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1 IIIB. AIDS 9:567-572, 1995
17. + T cells with a predominant Vβ usage during the primary immune responses to HIV. Nature 370:463-467, 1994
18. Merrifield RB: Solid phase peptide synthesis. J Am Chem Soc 85:2149-2154, 1963
19. Houghten RA: General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82:5131-5135, 1985
20. Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF: Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 145:2677-2685, 1990
21. Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 113: 512-519, 1990
22. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, Metcalf JA, Masur H, Lane HC: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study. N Engl J Med 332:567-575, 1995
23. Pedersen C, Sandstrom E, Petersen CS, Norkarans G, Gerstoft J, Karlsson A, Christensen KC, Hakansson C, Pehrson PO, Nielsen JO, Jurgensen HJ, Scandinavian Isoprinosine Study Group: The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 322:1757-1763, 1990
24. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, Deyton L, Davey RT Jr, Falloon J, Polis A, Salzman NP, Baseler M, Masur H, Fauci AS: Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: A randomized, placebo-controlled trial. Ann Intern Med 112:805-811, 1990
25. Lane HC, Davey RT Jr, Sherwin SA, Masur H, Rook AH, Manischewitz JF, Quinnan GV, Smith PD, Easter ME, Fauci AS: A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 9:351-361, 1989
26. Lane HC, Siegel JP, Rook AH, Masur H, Gelmann EP, Quinnan GV, Fauci AS: Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Res Modif 3:512-516, 1984
27. Picard O, Achour A, Bernard J, Halbreich A, Bizzini B, Boyer V, Desgranges C, Bertho JM, Lachgar A, Polliotti B, Defere MC, Lanneval K, Imbert JC, Frottier J, Salaun JJ, Burny A, Zagury D: A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: Evidence for persistent cell-mediated immunity. J AIDS 5:539-546, 1992
28. Achour A, Lemhammedi S, M'Bika JP, Zagury JF, Moukrim Z, Willer A, Beix F, Burney A, Zagury D: Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18 IIIB peptide in an HLA-A11-immunized individual. AIDS Res Hum Retrovirus 10:19-25, 1994
29. Kahn JO, Sinangil F, Baenzier J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D: Clinical and immunological responses to HIV type 1 SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidyl ethanolamine in non-HIV-infected human volunteers. J Infect Dis 170:1288-1291, 1994
30. Kahn JO, Steimer KS, Baenziger J, Duliege AM, Feinberg M, Elbeik T, Chesney M, Murcar N, Chernoff D, Sinangil F: Clinical, immunologic, and virologie observation related to HIV type-1 infection in a volunteer in a HIV-1 vaccine clinical trial. J Infect Dis 171:1343-1347, 1995
31. Nehete PN, Casement KS, Arlinghaus RB, Sastry KJ: Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp120. Cell Immunol 160:217-223, 1995
32. Casement KS, Nehete PN, Arlinghaus RB, Sastry KJ: Cross-reactive cytotoxic T lymphocytes induced by V3 loop peptides from different strains of human immunodeficiency virus type 1. Virology 211:261-267, 1995
33. Nara PL, Merges MJ, Conley SR: Evidence of cryptic V3 epitope(s) on native HIV-1 virions: Immunophysicochemical analysis. In Vaccines 94, F Brown, R Chanock, H Ginsberg, E Borrhy (eds). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1994, pp 155-159
34. Kohler H, Muller S, Nara PL: Deceptive imprinting in the immune response against HIV-1. Immunol Today 15(10):475-478, 1994
35. ROOS MTL, Miedema F, Koot M, Tersmette M, Schaasberg WP, Coutinho RA, Schellekens PTA: T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects. J Infect Dis 171:531-536, 1995
36. Koot M, Schellekens PTA, Mulder JW, Lange JM, Roos MT, Coutinho RA, Tersmette M, Miedema F: Viral phenotype and T-cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 168:733-736, 1993
37. Boucher CAB, Lange JMA, Miedema F, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA, Tersmette M: HIV-1 biological pheno-type and development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 6:1259-1264, 1992
38. Gruters RA, Tepstra FG, Lange JM, Roos MT, Harkema T, Mulder JW, DeWolf F, Schellekens PT, Miedema F: Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake. AIDS 5:43-47, 1991
39. Sastry KJ, Arlinghaus RB: A novel HIV vaccine strategy. Hematol Pathol 4:157-159, 1990
40. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM: A strategy for prophylactic vaccination against HIV. Science 260:1270-1272, 1993